Popular on Innoget
Publications
- View more
 | Seeking technologies to reduce GHGs in all aspects of the supply chain and manufacturing process. |
|
PepsiCo is committed to reducing GHG emissions from seed to shelf. We are looking to engage with partners who can assist us in our goal of reducing GHG 20% by 2030 and achieving net-zero emissions by 2050. As new technologies emerge, efficiencies will be gained and PepsiCo aims to remain at the forefront of best practices in the food and beverage industry. PepsiCo is seeking technologies to reduce GHGs in all aspects of the supply chain and manufacturing process. Solutions may be in one or more of the following areas: • Agriculture – sustainable farming and the reduction of GHG intensive fertilizers • Manufacturing – adopting energy efficient manufacturing processes; novel methods for utilizing waste; use of renewable thermal energy at scale • Packaging – alternative packaging materials and formats that reduce GHGs • Distribution – technologies to assist in the efficiency of our company-owned and third party fleet |
| | Seeking Recyclable Closure for Paper Beverage Bottles |
|
We are seeking technologies for a re-closable fiber-based closure for a paper beverage bottle that can be recycled in the paper stream. |
 | Seeking Glue-free and Plastic-free closure of paper packaging |
|
We are looking for a technology to seal paper packaging materials (paper only with no plastic coating) without using traditional glues or any other additive. For a sustainable packaging application, we're looking for a technology to seal or crimp kraft paper without using glue or plastic coating applied on the paper. Ideally, we want to seal 100% untreated paper without adding any other chemicals. Our preferred solution would be a folding of the packaging material |
 | Partnering Opportunity: Effervescent Powders for Inhalation |
|
University of Alberta and Alberta Health Services researchers have jointly developed a new type of dry-powder inhalable carrier particle with an active release mechanism to disperse therapeutics more effectively. Most advanced product candidate based on this delivery system is an inhalable effervescent doxorubicin nanoparticle formulation; it demonstrated significantly improved survival time in a small cell lung cancer mouse model. |
 | Improving stem cell culture using carnivorous plants |
|
Mesenchymal Stem Cells (MSCs) are multipotent precursor cells with the unique capacity to self-renew, proliferation and transformation into specialized cells present in many body tissues, such as muscle, adipose tissue, fibroblasts, cartilage, tendons, and nervous tissue. They are also characterized by the ability to affect the immune system by secretion of compounds that support the immune response directed among others against bacteria and parasites. They have properties enabling the secretion of chemical compounds that stimulate the formation of new blood vessels. All these attributes make them applicable in regenerative medicine, transplantology and in the treatment of many diseases. The umbilical cord blood and Wharton’s jelly MSCs are the sources from which MSCs are obtained. Due to the small amount of MSCs in the starting material, it is necessary to lead in vitro cultures to obtain sufficient numbers of cells that can be administered to the patient. Methods of isolation and culture of mesenchymal stem cells, including the growth medium, play a crucial role in obtaining the appropriate biological material that guarantees therapeutic success. Therefore, continuous improvement of procedures for isolating and in vitro culturing of MSCs is extremely important. The subject of the offer is a method of culturing mesenchymal stem cells using secretions from carnivorous plants, which increase cell adherence and proliferation, counteract their transformation into specialized cells, therefore, they longer maintain their pluripotency. |
 | Stable inhibitors of the 5-lipoxygenase pathway for treating Asthma and Cancer |
|
The University of Leipzig has patented a series of Carborane-Based Inhibitors of the 5-LO Lypoxygenase pathway. These inhibitors are selectively cytotoxic towards several leukotriene-dependend melanoma and colon cancer cell lines., while leaving non-malignent cells intact. Furthermore, these inhibitor analogues have shown co-inhibition of heat shock proteins necessary for tumor development in such cell lines. Experimental results on mice showed promising results. Moreover, since these compounds have a high content of boron, they may also be suitable for Boron Neutron Capture Therapy (BNCT), a binary cancer therapy that uses selective boron compounds and thermal neutrons. Furthermore, leukotriene inhibition could be useful in the treatment of asthma, as their production is related to inflammatory responses. The BBZ is looking for organzations interested in acquiring this technology offer, helping perform precilinical and clinical studies, and ultimately leading to the licensing of it. |
Job opportunities
Introducing Innoget Jobs
Great innovation projects are built with
talented and creative people.
